Antitumor activity of tamoxifen loaded solid lipid nanoparticles on induced mammary tumor gland in sprague-dawley rats

African Journal of Biotechnology

Volumn 9, Issue 43, 2010, Pages 7337-7345

  Abbasalipourkabir, Roghaieh ^a   Salehzadeh, Aref ^a   Abdullah, Rasedee ^b  

^a HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY PUTRA MALAYSIA   (Malaysia)

Author keywords

Mammary tumor gland; Sprague dawley rat; Tamoxifen loaded solid lipid nanoparticle

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; LACTATE DEHYDROGENASE; SOLID LIPID NANOPARTICLE; TAMOXIFEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOCHEMISTRY; BREAST TUMOR; CHROMATIN CONDENSATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; IN VIVO STUDY; LIPOPHILICITY; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; TRANSMISSION ELECTRON MICROSCOPY; TUMOR CELL; TUMOR VOLUME;

ANIMALIA; RATTUS;

EID: 78549263693     PISSN: 16845315     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Abdel-Kader F, Hemieda El-Sayed (2007). Influence of gender on tamoxifen-induced biochemical changes in serum of rats. Mol. Cell Biochem. 301: 137-142.
2. Beresford MJ, Wilson GD, Makris A (2006). Measuring proliferation in breast cancer: practicalities and applications. Breast Cancer Res. 8: 216-222.
3. Carlsson G, Gullberg B, Hafstrom L (1983). Estimation of liver tumor volume using different formulas-an experimental study in rats. J. Cancer Res. Clin. Oncol. 105: 20-23.
4. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM (1994). Endometrial cancer in tamoxifen treated breast cancer patients. J. Natl. Cancer Inst. 85: 527-537.
5. Han X, Liehr JG (1992). Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res. 52: 1360-1363.
6. Jacob D, Davis J, Fang B (2004). Xenograftic tumour models in mice for cancer research, a technical review. Gene Ther. Mol. Biol. 8: 213-219.
7. Jordan VC (1993). A current view of tamoxifen for the treatment and prevention of breast cancer. Br. J. Pharmacol. 110: 507-517.
8. Jores K, Haberland A, Wartewig S, Mäder K, Mehnert W (2005). Solid Lipid Nanoparticles (SLN) and Oil-Loaded SLN Studied by Spectrofluorometry and Raman Spectroscopy. Pharm. Res. 22: 1887-1897.
9. Kim SA, Kim HW, Kim DK, Kim SG, Park JC, Kang DW, Kim SW, Ahn SG, Yoon JH (2006). Rapid induction of malignant tumor in Sprague-Dawley rats by injection of RK3E-ras cells. Cancer Lett. 235: 53-59.
10. Koukourakis MI, Kontomanolis E, Giatromanolaki A, Sivridis E Liberis V (2008). Serum and Tissue LDH Levels in Patients with Breast/Gynaecological Cancer and Benign Diseases. Gynecol. Obster. Invest. 67: 162-168.
11. Lam HY (1984). Tamoxifen is a calmoduline antagonist in the activation of cAMP phosphodiesterase. Biochem. Biophys. Res. Co, 118: 27-32.
12. Luo Y, Chen D, Ren L, Zhao X, Qin J (2006). Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability. J. Control Release, 114: 53-59.
13. Lynch ED, Gu R, Pierce C, Kil J (2005). Combined oral delivery of ebselen and allopurinol reduces multiple cisplatin toxicities in rat breast and ovarian cancer models while enhancing anti-tumor activity. Anti-Cancer Drug, 16: 569-579.
14. Manlekar S, Kong ANT (2001). Mechanisms of tamoxifen-induced apoptosis. Apoptosis, 6: 469-477.
15. Memisoglu-Bilensoy E, Vural I, Bochot A, Renoir JM, Ducheneb D, Hincal AA (2005). Tamoxifen citrate loaded amphiphilic β-cyclodextrin nanoparticles: In vitro characterization and cytotoxicity. J. Control Release, 104: 489-496.
16. O'Brian CA, Liskam RM, Solomon DH, Weinstein IB (1985). Inhibition of protein kinase C by tamoxifen. Cancer Res. 45: 2462-2465.
17. Padmavathi R, Senthilnathan P, Chodon D, Sakthisekaran D (2006). Therapeutic effect of paclitaxel and propolis on lipid peroxidation and antioxidant system in 7, 12 dimethyl benz(a)anthracene-induced breast cancer in female Sprague Dawley rats. Life Sci. 78: 2820-2825.
18. 10: Effect on lipid peroxidation and antioxidants in mitochondria. Chem. Biol. Int. 152: 49-58.
19. Railo M, Lundin J, Haglund C, Von Smitten K, Nordling S (2006). Ki-67, p53, ER receptors, ploidy and S phase as long-termpr ognostic factors in T1 nodenegative breast cancer. Tumor Biol. 1: 45-51.
20. Sandhya Mishra D.C, Sharma Praveen Sharma (2004). Studies of biochemical parameters in breast cancer with and without metastasis. Ind. J. Clin. Biochem. 19: 71-75.
21. Schubert MA, Müller-Goymann CC (2005). Characterization of surfacemodified solid lipid nanoparticles (SLN): Influence of lecithin and nonionic emulsifier. Eur. J. Pharm. Biopharm. 61: 77-86.
22. Tatarczuch L, Philip C, Lee CS (1997). Involution of the sheep mammary gland. J. Anat. 190: 405-416.
23. Wang JY, Xu BH, Tian LJ, Wang Y (2006). Clinical characteristics and potential prognostic factors of breast cancer patients with liver metastases. Zhonghua Zhong Liu Za Zhi, 28: 612-616.
24. Young S, Hallowes RC (1973). Tumors of the mammary gland. In Pathology of tumors in laboratory animals, Tumors of the rat, part 1, V.S. Turusov, Ed., IARC, Switzerland, 1: 31-38.
25. Yuan H, Huang LF, Du YZ, Ying XY, You J, Hu FQ, Zeng S (2007). Solid lipid nanoparticles prepared by solvent diffusion method in a nonreactor system. Colloidd Surfaces B: Biointerface, 61: 132-137.